JPRN-UMIN000008793已完成2 期
Phase II study of remission induction therapy with bendamustine and rituximab combination (BR) therapy followed by consolidation therapy with 90Y-labeled iburitumomab tiuxetan for relapsed follicular lymphoma.(BRiZ2012 protocol) - Phase II study of remission induction therapy with BR therapy followed by consolidation therapy with 90Y-labeled iburitumomab tiuxetan for relapsed follicular lymphoma.
Society of Lymphoma Treatment in Japan (SoLTJ)0 个研究点目标入组 28 人开始时间: 2012年9月3日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 28
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 75years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •Histologically confirmed CD20 negative lymphoma by biopsy at the time of diagnosis or relapse. Having active double or multiple cancer. Having infectious disease with poor control (including active tuberculosis ). Having the central nervous system infiltration of the lymphoma. Intolerant to the drugs using in this study. If any of HIV antibody, HBs antigen or HCV antibody positivity. Pregnant (including possibility), nursing women. Had received bendamustine administration previously.
研究者
相似试验
进行中（未招募）
2 期
TOP-ILD studyProgressive pulmonary fibrosisinterstitial pneumonia, IP, PPFJPRN-jRCTs071230004Okamoto Isamu32
尚未招募
Unknown
Prediction of therapeutic efficacy of ulcerative colitis based on gene expression in the colonic mucosa.ulcerative colitisJPRN-UMIN000050517Kyoto Prefectural University of Medicine100
已完成
2 期
A phase II study of the remission induction and maintenance therapy by rituximab for rituximab naive low grade B cell lymphoma.low grade B cell lymphomaJPRN-UMIN000001191Clinical Hematology Study Group of National Hospital Organization(CHSG-NHO)42
进行中（未招募）
不适用
Phase II study of first line treatment of chronic graft versus host disease with the association of ciclosporine, corticosteroids and Rituximab - R-GVHDChronic graft versus host diseaseMedDRA version: 12.1Level: LLTClassification code 10066261Term: Chronic graft versus host diseaseEUCTR2009-016898-14-FRCHU de Nantes
进行中（未招募）
不适用
A phase II study for the treatment of patients with splenic marginal lymphoma with the combination of Cyclophosfamide, Vincristine, Liposomal Doxorubicin, Predinisone and RituximabTreatment of patients with newly diagnosed splenic marginal non Hodgkin lymphomaMedDRA version: 9.1Level: LLTClassification code 10062113Term: Splenic marginal zone lymphomaEUCTR2005-000693-45-ITG.I.S.L. - GRUPPO ITALIANO STUDIO LINFOMI